Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)‘s stock had its “buy” rating restated by research analysts at Mizuho in a research report issued to clients and investors on Friday.

A number of other analysts also recently issued reports on AERI. Canaccord Genuity set a $65.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 8th. HC Wainwright set a $69.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Stifel Nicolaus reissued a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a research report on Friday, July 28th. Zacks Investment Research raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, BidaskClub raised shares of Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have given a buy rating to the stock. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $69.71.

Aerie Pharmaceuticals (NASDAQ:AERI) traded up $1.15 on Friday, reaching $64.85. 422,983 shares of the company were exchanged, compared to its average volume of 780,646. Aerie Pharmaceuticals has a 12-month low of $32.35 and a 12-month high of $66.25. The company has a debt-to-equity ratio of 0.67, a current ratio of 22.44 and a quick ratio of 22.45.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.02. analysts expect that Aerie Pharmaceuticals will post -3.09 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Aerie Pharmaceuticals’ (AERI) Buy Rating Reaffirmed at Mizuho” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/04/aerie-pharmaceuticals-aeri-buy-rating-reaffirmed-at-mizuho.html.

Several institutional investors have recently added to or reduced their stakes in AERI. UBS Asset Management Americas Inc. boosted its stake in shares of Aerie Pharmaceuticals by 97.3% during the 1st quarter. UBS Asset Management Americas Inc. now owns 12,430 shares of the company’s stock valued at $564,000 after buying an additional 6,130 shares during the last quarter. Karp Capital Management Corp purchased a new position in shares of Aerie Pharmaceuticals during the 1st quarter valued at approximately $213,000. FMR LLC boosted its stake in shares of Aerie Pharmaceuticals by 178.7% during the 1st quarter. FMR LLC now owns 320,500 shares of the company’s stock valued at $14,535,000 after buying an additional 205,500 shares during the last quarter. Teachers Advisors LLC boosted its stake in shares of Aerie Pharmaceuticals by 5.1% during the 1st quarter. Teachers Advisors LLC now owns 49,726 shares of the company’s stock valued at $2,255,000 after buying an additional 2,402 shares during the last quarter. Finally, California Public Employees Retirement System purchased a new position in shares of Aerie Pharmaceuticals during the 1st quarter valued at approximately $231,000. Institutional investors own 94.71% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.